ABT-263 (Navitoclax) 化学構造
分子量: 974.61




Quality Control & MSDS


  • Compare Bcl-2 Inhibitors
  • 研究分野



製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。





≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.

プロトコル (参考用のみ)



Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.



細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.



動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download ABT-263 (Navitoclax) SDF
分子量 974.61


CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)

Click to enlarge
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (35)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。


Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID